Work

Clinical uses of intravenous immunoglobulin

Year: 2005
Type: review
Abstract: Intravenous immunoglobulin (IVIG) is a blood product prepared from the serum of between 1000 and 15 000 donors per batch. It is the treatment of choice for patients with antibody deficiencies. For this indication, IVIG is used at a ‘replacement dose’ of 200–400 mg/kg body weight, given approximately 3-weekly. In contrast, ‘high dose’ IVIG (hdIVIG), given most frequently at 2 g/kg/month, is used as an ‘immunomodulatory’ agent in an increasing number of immune and inflammatory disorders. Initial use of hdIVIG was for immune thrombocytopenic purpura (ITP) in children [1]. The clinical specialities using the largest amounts of IVIG are neurology, haematology, immunology, nephrology, rheumatology and dermatology. IVIG has had a major impact on the treatment of neurological disorders including dermatomyositis, Guillain–Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), myasthenia gravis and stiff person syndrome. In haematology it is used to treat immune cytopenias, parvovirus B19 associated red cell aplasia, hypogammaglobulinaemia secondary to myeloma and chronic lymphatic leukaemia and post-bone marrow transplantation. In immunology IVIG is used in the treatment of primary antibody deficiency (PAD), in nephrology, rheumatology and ophthalmology it has been used to treat vasculitis, systemic lupus erythematosis (SLE), mucous membrane pemphigoid and uveitis and in dermatology it is used most commonly to treat Kawasaki syndrome, dermatomyositis, toxic epidermal necrolysis and the blistering diseases (Table 1). Major uses of intravenous imunoglobulin (IVIG). IVIG is used mainly at high dose (2 g/kg) for the indications listed in neurology, haematology, rheumatology, dermatology and others while in immunology replacement doses (0·4 g/kg) are given. The uses listed are not exhaustive, but aim to cover the disorders for which IVIG is most frequently used and whether a randomized controlled (RCT) study or Cochrane review (CR) is available. CVID, common variable immunodeficiency; XLA, X-linked agammaglobulinaemia; HIGM, hyper-IgM syndrome; WAS, Wiskott Aldrich syndrome; CLL, chronic lymphocytic leukaemia. *Blistering diseases include pemphigus vulgaris, pemphigus folaceous, bullous and nodular pemphigoid, mucous membrane pemphigoid, gestational pemphigoid, epidermolysis bullosa acquisita and linear IgA disease. Major uses of intravenous imunoglobulin (IVIG). IVIG is used mainly at high dose (2 g/kg) for the indications listed in neurology, haematology, rheumatology, dermatology and others while in immunology replacement doses (0·4 g/kg) are given. The uses listed are not exhaustive, but aim to cover the disorders for which IVIG is most frequently used and whether a randomized controlled (RCT) study or Cochrane review (CR) is available. CVID, common variable immunodeficiency; XLA, X-linked agammaglobulinaemia; HIGM, hyper-IgM syndrome; WAS, Wiskott Aldrich syndrome; CLL, chronic lymphocytic leukaemia. *Blistering diseases include pemphigus vulgaris, pemphigus folaceous, bullous and nodular pemphigoid, mucous membrane pemphigoid, gestational pemphigoid, epidermolysis bullosa acquisita and linear IgA disease. In this paper, we review recent developments in the understanding of mechanisms of action of IVIG, the major current clinical areas of use concentrating on conditions with a better established evidence base and discuss emerging areas of use of IVIG. The mechanisms of action of therapeutic immunoglobulin are complex, but over recent years important advances in understanding have been made (summarized in Fig. 1) [2]; the predominant mechanism operating in a particular situation appears to depend on both the immunoglobulin dose and the pathogenesis of the disease under consideration. Immunomodulatory actions of intravenous immunoglobulin. Intravenous immunoglobulin (IVIG), may for the purposes of understanding, be thought of as four separate components: (1) actions mediated by the variable regions F(ab′)2, (2) actions of Fc region on a range of Fc receptors (FcR), (3) actions mediated by complement binding within the Fc fragment and (4) immunomodulatory substances other than antibody in the IVIG preparations. It should be remembered that not all the potential mechanisms of action fit perfectly into the groupings and that several mechanisms may act concurrently (TCR, T cell receptor; ADCC, antibody dependent cellular cytotoxicity; DC, dendritic cell). Commercial IVIG preparations contain a ‘species repertoire’ of antibody specificities, resulting in neutralization of a wide range of antigens including pathogens and superantigens [3]; there is, however, significant batch-to-batch variation in the concentration of a particular antibody [4]. IVIG has been shown to have a considerable inhibitory effect on mitogen-induced T cell proliferation in vitro[5]. This effect has been shown for intact IgG, with less evidence for a role for Fc fragment [6]. Both antigen-dependent and antigen-independent responses are inhibited by IVIG in a dose-dependent manner [7]. IVIG has been shown to suppress the proliferation of antigen-specific T cells without inducing apoptosis, the cells remaining refractory to induction of apoptosis by CD95 ligation [8]. In toxic epidermal necrolysis (TEN), which is mediated by over-expression of fas-ligand, inducing apoptosis in keratinocytes, causing extensive dermal/epidermal separation, IVIG contains fas-blocking antibodies reducing keratinocyte death in this condition [9]. In addition in atopic dermatitis T cell-mediated, Fas-induced keratinocyte apoptosis is inhibitied by IVIG [10]. Additional studies show that IVIG causes the arrest of cells at the G0/G1 phase of the cell cycle, and inhibits cells from entering S-phase [11]. In contrast to these studies IVIG has been demonstrated to induce apoptosis in leukaemic lymphocytes and monocytes as well as normal tonsillar B cells, an effect mediated at least in part by anti-CD95 antibodies present within the IVIG preparations [12]. Taken together, these studies show that although IVIG appears to be broadly anti-apoptotic and cause cell cycle arrest, under certain conditions it may also induce apoptosis. IVIG has also been shown to reduce adhesion of T cells to extracellular matrix following activation by phytohaemagglutinin (PHA) or phorbol myristate acetate (PMA) [13] and contains antibodies to the Arg-Gly-Asp (RGD) motif, the attachment site for a number of adhesive extracellular matrix proteins and β1, β3 and β5 integrins [14]. IVIG contains natural IgG antibodies which are germline encoded and occur in the absence of infection or vaccination and the importance of these has been demonstrated in a study into the in vitro differentiation of dendritic cells (DCs) from patients with X-linked agammaglobulinaemia who lack B cells and antibodies. Differentiation of DCs was shown to be impaired, and the defect was reversed by natural antibodies reactive with CD40 [15]. Anti-idiotypes present in IVIG may also be responsible for the success of IVIG treatment of ITP; IVIG prepared from multiparous women contains many more anti-idiotypes to human HLA antigens, and can inhibit alloimmunization to HLA [16]. IVIG may also contain antibodies to a range of immunologically important molecules such as interleukin (IL)-1α, tumour necrosis factor (TNF)-α and interferon (IFN)-γ[17–19] as these have been demonstrated in the sera of healthy individuals. IVIG contains antibodies against the beta chain of the T cell receptor and also against CD5 and CD4 [20–22] The binding of immunoglobulin Fc to inhibitory (FcγRIIb) and activating (FcγRI and FcγRIII) Fc receptors exerts numerous effects. Competitive binding of IVIG to FcR on macrophages in the reticuloendothelial system may alter clearance of cells in autoimmune cytopenias [23]. FcγRIII are particularly involved and the Fc region of the Ig is essential [24]. Binding of IVIG to FcγRIIb deactivates phagocytosis. Bruhns and colleagues demonstrated recently that this process involves colony stimulating factor (CSF)-1 dependent macrophages which they claimed act as ‘sensors’ for IVIG Fc regions [25]. This results in the induction of FcγRIIb on CSF-1 independent macrophages, which in turn raises the threshold for FcγRIII-mediated activation and inflammation. FcR binding has been shown to inhibit dendritic cell maturation at immunomodulatory doses [26]. FcR may be important in cytokine changes which down-regulate reticuloendothelial function [27]. The interpretation of changes in cytokine levels following IVIG is complicated by the different methodologies used in measurement, the presence of antagonists or soluble receptors and in vitro versus in vivo data. IVIG has been shown to induce IFN-γ, IL-6 and IL-1ra (IL-1ra by up to 1000 fold), while IL-1 and IL-2 are down-regulated [28,29–32]. Changes in cytokines may also be affected by the pattern of expression prior to IVIG and the effect in vivo is difficult to predict from in vitro studies. IVIG may interfere with antibody dependent cellular cytotoxicity (ADCC) by competing for Fc receptor binding with antibodies directed towards cellular targets. In addition, monomeric IgG within IVIG may block access of aggregated IgG to FcγRIII. IVIG can also act synergistically with dexamethasone in suppressing lymphocyte activation as measured by a shift in the dexamethasone dose–response curve by 1 log-fold; this was associated with significantly improved glucocorticoid receptor binding affinity [33]. Saturation of the neonatal FcR (FcRn) may enhance endogenous IgG catabolism, reducing autoantibody levels by as much as 40% in some models [34]. Low-affinity FcR (FcγRII and III) saturation by monomeric IgG occurs at clinically achievable levels, even though these are predominantly receptors for aggregated IgG. This suggests that functional blockade of low affinity FcR is important [35]. The relative abundance of activating and inhibiting FcR, and hence the response to IVIG, is influenced by the cytokine balance. Th1 cytokines including IFN-γ and TNF-α induce activating FcR, and down-regulate inhibitory FcR. Th2 cytokines including IL-4 and IL-13 have the opposite effect. Clinically this is reflected in the response of patients with childhood immune thrombocytopenia (ITP) to IVIG, in that patients who go into remission tend to have induction of Th2 cytokines. This differential control of FcR expression, and hence response to IVIG, may be due to cross-linking of FcRI on macrophages which down-regulates IL-12 production and hence Th1 cytokines. Other IVIG effects include modulation of complement activity, demonstrated particularly by the effects of IVIG in dermatomyositis, a complement-dependent microangiopathy. Although in fact beneficial, IVIG as well as immune complexes results in the generation of nascent C3b, and should theoretically be proinflammatory. Indeed small doses of IVIG produce measurable classical and alternative pathway activation [36]. However, the Fc region appears to scavenge C3a and C5a [37]. High-dose IVIG inactivates immune complexes, selectively attenuating complement amplification. IVIG itself may contain cytokines and other molecules including soluble cytokine inhibitors, soluble CD4 and major histocompatibility complex (MHC) class II [38]. Stabilizing agents, mainly various sugars, can also exert an effect, both maltose and sucrose, at concentrations present in commercial IVIG preparations, can inhibit PHA- and to a lesser extent, PMA-induced proliferative responses in vitro[39] (reviewed in [2]). Immunoglobulin therapy first established itself as an immunomodulatory agent in the management of (ITP) [23], although in adult ITP several studies now suggest that steroids alone can increase the platelet count unless clinical features of haemorrhage have developed [40]. Haemolytic anaemia in sickle cell disease and after transfusion in lymphoma can occur despite being direct antiglobulin test (DAT) and alloantibody negative. Provan outlines how IVIG was shown to prevent this form of anaemia in a small series of three patients from Win's group described in poster form only − suggesting that other mechanisms, apart from FcR blockade, are also relevant [41]. Acquired haemophilia has also been shown to respond to hdIVIG therapy [42]. However, despite initial success a recent meta-analysis suggests that hdIVIG is still associated with a poor complete response rate and is not recommended as first line therapy. Haematologists have traditionally used IVIG to prevent cytomegalovirus (CMV) infection following bone marrow transplantation (BMT). Mühleisen and colleagues showed that infection rates and survival are similar, whether or not IVIG is given [41]. IVIG should probably be reserved only for patients who are hypogammaglobulinaemic (IgG < 4 g/l) after BMT. Paediatricians have used IVIG at 0·5 g/kg in a single dose on the first day of life in children with haemolytic disease of the newborn [43]. This is effective at reducing haemolysis and hence reduces the need for exchange transfusions. Adults with secondary antibody deficiency (SAD) associated with chronic lymphocytic leukaemia and myeloma have both been shown to benefit from IVIG replacement therapy, if incapable of mounting an adequate response to diagnostic immunization with polysaccharide antigens (Pneumovax II) [44,45]. Although the clinical of IVIG replacement in is has been with alone has been shown to be effective in with a significant of effects for alone with IVIG in these disease The impact of immunization with the on the of disease in patients with and myeloma is to be considerable body of evidence in a Cochrane review has shown that IVIG is to exchange in the treatment of patients with Guillain–Barre IVIG is effective in with disease or in who treatment more than 2 after the of is is evidence that IVIG with exchange is of steroids with IVIG benefit Although there are randomized of IVIG in childhood the evidence from adult has been for IVIG to be recommended for children with motor neuropathy with which for motor disease but is by the presence of motor IVIG is the treatment of choice in as steroids have effect and may disease. randomized controlled have shown that IVIG neurological and may IVIG therapy is in many patients This is a neuropathy clinically by and and IVIG is steroids in some with the treatment for from randomized controlled that IVIG is of to steroids and at least in the IVIG is as therapy for given the associated with therapy. patients with and with motor may after treatment with IVIG and steroids benefit is The inflammatory that is of is associated with a complement-dependent in affected The of IVIG in patients with refractory to therapy was shown in a randomized in IVIG is to steroids as therapy for is In refractory IVIG has been shown to be in but has not been to a randomized from randomized not the use of IVIG in body gravis an autoimmune neurological is by by antibodies to the The only to showed that IVIG was as effective as exchange for In IVIG is reserved for patients with refractory to or of therapy or in of The which with a of and features is associated with antibodies to is associated with in of patients in it as a IVIG has been shown in a to produce in IVIG is reserved for patients with who are to therapy. The is a by and associated with high of antibodies to antibodies the for the of a major inhibitory is evidence from the only that IVIG significantly reduces in this disease that enhance only produce a in IVIG is to be the treatment of The effects of IVIG in reducing the of in is of a to that with and acetate recent Cochrane review of IVIG in that while there was some evidence to use to prevent in there a need for studies to more to be In contrast, IVIG is of benefit in secondary the of immunoglobulin replacement for primary antibody deficiency in the studies immunoglobulin with or a treatment or immunoglobulin replacement made in patients with endogenous B cell the of the of immunoglobulin replacement therapy in hypogammaglobulinaemia was up in it was that a be of evidence from the that Ig replacement was effective in the of in The first major randomized of immunoglobulin replacement therapy with the of intravenous immunoglobulin (IVIG) in the and showed that IVIG was as or to in reducing infection in even with the use of small doses of IVIG at The of the dose of IVIG was by who showed that of a serum IgG in of using doses of g/kg in a in and in to patients who studies to the whether more immunoglobulin is better have results which are to be due to in study dose and the lack of a between different of the is however, clinical that IgG levels should be within the normal range for patients with with patients from studies a in the of in IVIG is although the of of in some patients with common variable despite IgG levels in of is and suggests that other than infection may be in that of IgG to the occurs mainly after of there has been much in the role of IVIG as against infection in Although studies some a Cochrane meta-analysis of studies including approximately has shown that IVIG a to the of but not reduce associated or The meta-analysis that there is for randomized of IVIG in or low the role of IVIG as therapy for or neonatal is not by a recent Cochrane meta-analysis which showed that the of with IVIG was only of The conditions with the of evidence are Kawasaki therapy toxic epidermal necrolysis and the blistering diseases vulgaris, bullous pemphigoid, epidermolysis bullosa mucous membrane pemphigoid, linear IgA disease and gestational in particular pemphigus Other conditions the evidence mainly of series or are atopic dermatitis chronic immune and Kawasaki disease is an childhood first described in in the by Kawasaki the of Kawasaki disease is the most common cause of disease in the developed The include a changes in the and and of the with associated of the and the it that many patients developed such as on This was associated with a significant rate from have been including controlled and a Cochrane review on the use of IVIG in this disease The are that children the diagnostic for Kawasaki disease should be given as first line treatment a single dose of 2 g/kg of IVIG within of the of epidermal necrolysis is a by an of treatment to mechanism for is extensive keratinocyte apoptosis, a process that can be inhibited in vitro by antibodies present in IVIG [9]. The is to be a form of by mucous membrane and < of the body The therapeutic potential of IVIG in and has not been in controlled randomized studies and more is however, a number of studies have shown a in blistering and with IVIG In a IVIG at an dose of 2 g/kg in patients and however, an high rate due to was in this Taken together, the evidence suggests a potential benefit from a single cycle of 2 g/kg of IVIG with the of some at doses g/kg) on now use IVIG as first line treatment for in the of the is an autoimmune blistering disease with to The disease can the and mucous of the and are now more than patients who have been with IVIG in the the of to treatment with 2 g/kg given at disease remission is it is in many to reduce and IVIG. In of these a controlled of IVIG in is to potential therapeutic This also to pemphigoid High-dose IVIG has been shown in and randomized studies to be a therapy in antibody systemic refractory to therapy. The use of IVIG as therapy in without has results in but has not been to patients with major Although IVIG has been used in or series of patients with other small with use in is with due to the of by the of immune complexes of IgG and the factor of The success of high dose IVIG in series of patients with is to be to the of a randomized In patients with proliferative lupus who have remission following therapy, IVIG was shown to be as as in remission IVIG as a therapeutic agent in is given the recent success of in lupus The success of IVIG therapy in an series of patients with toxic is by the that IVIG contains antibodies and the of from patients with to block cytokine production there are randomized of IVIG in is a autoimmune uveitis in frequently therapy. The results of studies in both and uveitis are however, there have been randomized controlled to these initial all IVIG preparations are for use in antibody not all have a for the wide range of immunomodulatory indications for which IVIG is in the process Fc receptor function and complement it is not to all IVIG preparations as a the of different IVIG have only been in Kawasaki disease in a group of patients with primary antibody deficiency IVIG was by a product For the and the potential in of it be if patients treatment are on the IVIG of whether IVIG is used for antibody replacement or 2 the important of IVIG preparations in the with high of antibodies on a of IgA deficiency should be with a low levels of IgA to the of For patients with are the of is with IVIG preparations as a and of the more important and frequently effects is shown in however, a more is the of this and the is to the review by effects of intravenous immunoglobulin therapy. occur with low or predominantly associated with IVIG. effects of intravenous immunoglobulin therapy. occur with low or predominantly associated with IVIG. of IVIG preparations in the that while the process for all IVIG have some have an of IVIG preparations in the that while the process for all IVIG have some have an has been a in the use of intravenous immunoglobulin (IVIG) for an number of It is a product with an without the effects of steroids or other have been numerous recent advances in understanding of the mechanisms of action of IVIG in many of the conditions for which it is being but there is still much to be IVIG has had a major impact in neurology, haematology, immunology, rheumatology and dermatology. The for IVIG are of the itself and the associated with of the effects are by of the prior to with and and of It is however, that effects be more as the dose given and effects on It be important to increase the evidence base for IVIG in many conditions to therapeutic In addition, there have been studies for hdIVIG and still of which such as and the therapeutic Although not the use of IVIG is being in a range of conditions including adult syndrome, and even disease. IVIG to be of in these it is to have major for as many of the conditions are common and on the of IVIG studies need to of and mechanism of action which may the to treatment IVIG. It is also however, that controlled in many of the conditions may be difficult to and such as disease may be to and for and for of the
Authors: S Jolles, W A C Sewell, S A Misbah
Language: English
Subfield: Immunology
Open Access status: green
OpenAlex ID: W2104373525
FWCI: 1.365
Cites: 132
Cited by: 380
Related to: 10